OTCMKTS:ATMS Artemis Therapeutics (ATMS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Artemis Therapeutics Stock (OTCMKTS:ATMS) 30 days 90 days 365 days Advanced Chart Get Artemis Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume2,942 shsMarket Capitalization$55.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewArtemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.Read More… Receive ATMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATMS Stock News HeadlinesPurple Biotech Expands ATM Offering by $1.33 MillionJanuary 7, 2025 | msn.comThe Impact Of Utility ATMs On Financial AccessSeptember 13, 2024 | forbes.comTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what could be the biggest wealth opportunity since Bitcoin's early days.May 2, 2025 | Crypto 101 Media (Ad)Artemis 3 astronauts will walk on the moon with 4G-equipped spacesuitsSeptember 3, 2024 | yahoo.comITRM Iterum Therapeutics plcMarch 30, 2024 | seekingalpha.comMoon a la mode? Prada to design spacesuit for Nasa’s Artemis III missionOctober 10, 2023 | theguardian.comMarker Therapeutics gets new chief medical officerMay 8, 2023 | msn.comARTEMIS, a soccer-playing humanoid robot, is ready for the pitchApril 27, 2023 | finance.yahoo.comSee More Headlines ATMS Stock Analysis - Frequently Asked Questions How do I buy shares of Artemis Therapeutics? Shares of ATMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artemis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artemis Therapeutics investors own include SiteOne Landscape Supply (SITE), Nabriva Therapeutics (NBRV), Meta Platforms (META), Gemini Therapeutics (GMTX), ERYTECH Pharma (ERYP) and Bruush Oral Care (BRSH). Company Calendar Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous chemical products Sub-IndustryConsumer Goods Current SymbolOTCMKTS:ATMS CIK1062128 Webwww.artemis-therapeutics.com Phone(646) 233-1454Fax800-253-5177Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,360,000.00 Net Margins-299.54% Pretax Margin-299.54% Return on EquityN/A Return on Assets-425.51% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.12 Sales & Book Value Annual Sales$310,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares112,034,000Free Float103,687,000Market Cap$55.79 million OptionableNot Optionable Beta-1.92 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:ATMS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artemis Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artemis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.